Company Filing History:
Years Active: 2020
Title: Miwako Kakiuchi: Innovator in Cancer Diagnosis
Introduction
Miwako Kakiuchi is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of cancer research, particularly in the area of cancer diagnosis and therapeutic agent screening. Her innovative work has the potential to impact cancer treatment and detection significantly.
Latest Patents
Miwako Kakiuchi holds a patent for the "Use of RHOA in cancer diagnosis and inhibitor screening." This patent discloses a novel method for detecting cancer, as well as a method for screening inhibitors and anticancer agents that target cancer-related molecules. The patent details the use of the RHOA polypeptide, which has mutations, and a polynucleotide encoding this polypeptide as a therapeutic agent for cancer. Additionally, it describes a method for detecting cancer using the polypeptide or polynucleotide, along with a vector and a host cell comprising the polynucleotide. The patent also outlines a method for screening therapeutic agents for cancer that includes the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer that comprises siRNA with a silencing effect on the RHOA mutant. Miwako Kakiuchi has 1 patent to her name.
Career Highlights
Throughout her career, Miwako Kakiuchi has worked with notable organizations, including Chugai Pharmaceutical Co., Ltd. and The University of Tokyo. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Miwako Kakiuchi has collaborated with esteemed colleagues such as Hiroyuki Aburatani and Shumpei Ishikawa. These partnerships have further enhanced her research and innovation in cancer diagnosis and treatment.
Conclusion
Miwako Kakiuchi is a trailblazer in the field of cancer research, with her innovative patent offering new methods for diagnosis and treatment. Her work exemplifies the importance of innovation in the fight against cancer, and her contributions will continue to influence the field for years to come.